Neurophet Showcases AI Solutions for Brain Disease at BIO USA 2024

Neurophet's Participation at BIO USA 2024

Neurophet, a company specializing in artificial intelligence (AI) solutions for brain diseases, announced its participation in the annual BIO International Convention 2024 (BIO USA) set to take place from June 3 to 6 in San Diego, U.S. This event provides a unique platform for Neurophet to showcase their innovative AI-driven imaging services.

Imaging CRO Services for Alzheimer's Disease

One of the highlights of Neurophet's participation will be their Imaging Contract Research Organization (CRO) service, particularly useful in clinical trials for Alzheimer's disease treatments. This technology leverages MRI and PET scans to analyze medical images and biomarkers through their proprietary software, Neurophet AQUA for MRI analysis and Neurophet SCALE PET for PET image analysis.

Both software tools have received 510(k) clearance from the US Food and Drug Administration (FDA), ensuring they meet stringent standards for safety and effectiveness. Neurophet's Imaging CRO service is pivotal in maintaining high-quality and compliant image data throughout clinical trials.

Boosting Drug Development Success

The Imaging CRO service excels in offering reliable and consistent analysis results, enhancing the cost-efficiency and time-effectiveness of clinical trials. By providing precise image analysis, Neurophet aids pharmaceutical and biotech companies in increasing the success rates of new drug developments across various clinical trial stages, from patient group determination to efficacy evaluation and side-effect monitoring.

Strategic Partnership with AriBio

Neurophet has recently entered into a collaborative agreement with AriBio, a company focused on treating neurodegenerative disorders. This partnership aims to support global phase 3 clinical trials of AR1001, an oral Alzheimer's disease treatment. The collaboration highlights the growing trend of pharmaceutical companies partnering with AI firms to overcome challenges in drug development.

Expanding Opportunities at BIO USA

Neurophet's CEO, Jake Junkil Been, expressed the significance of their Imaging CRO service in advancing drug development processes for Alzheimer's disease. The AI-driven technology promises meaningful contributions to clinical trial success and operational efficiency. With scheduled meetings with various global pharmaceutical companies at BIO USA, Neurophet aims to foster valuable partnerships.

BIO USA is renowned as the world's largest bio industry event, attracting participation from pharmaceutical and bio companies, university research institutes, and investment entities. It serves as a prime venue for global partnering opportunities and showcases industry innovations.

About Neurophet

Founded in 2016 by Jake Junkil Been and Donghyeon Kim, Neurophet specializes in developing AI-based solutions for diagnosing, guiding treatment, and creating treatment devices for brain diseases. Their notable products include Neurophet AQUA for MRI analysis, Neurophet SCALE PET for PET image analysis, and Neurophet tES/TMS LAB for planning brain electric and magnetic stimulation treatments.

Neurophet is committed to enhancing the health and well-being of individuals with brain diseases. Through continuous growth and innovation, the company strives to pioneer AI solutions for brain health diagnostics and treatments.